IP Library Granted Patent US 11,512,139
Granted Patent B2
US 11,512,139 · App. 16/065,282 · Granted Nov 29, 2022

Chimeric antigen receptor with cytokine receptor activating or blocking domain

Inventors: Hinrich Abken (Meudt, DE); Andreas Hombach (Bruhl, DE)
Assignee: Miltenyi Biotec B.V. & Co. KG
C07K16/3007A61K39/00117C07K14/5434C07K14/7051C07K14/70521A61K2039/505C07K2317/622C07K2317/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,512,139
App. No.
16/065,282
Granted
Nov 29, 2022
Kind
B2
Abstract

The present invention provides a chimeric antigen receptor (CAR), comprising an extracellular part, at least one intracellular signaling domain, and at least one transmembrane domain, wherein the extracellular part of said CAR comprises a) at least one antigen binding domain, and b) at least one cytokine receptor activating or blocking domain. The invention also provides isolated nucleic acid molecule(s) encoding for the said CAR, a cell comprising said nucleic acid molecule(s), a cell expressing said CAR and therapeutic uses of said CAR.

Claims (11)

1. A single chain chimeric antigen receptor (CAR) polypeptide, comprising an extracellular part, wherein the extracellular part of the CAR comprises: a) a scFv and b) the amino acid sequence encoded by SEQ ID NO: 1.

2. The single chain CAR polypeptide according to claim 1 , wherein the scFv binds to carcinoembryonic antigen (CEA).

3. The single chain CAR polypeptide according to claim 1 , wherein the scFv binds to Mucin-1 (Muc1).

4. The single chain CAR polypeptide according to claim 1 , wherein the CAR comprises the amino acid sequence encoded by SEQ ID NO:4 or SEQ ID NO:5.

5. An isolated nucleic acid molecule encoding the CAR according to claim 4 .

6. A T cell comprising the nucleic acid molecule of claim 5 .

7. A pharmaceutical composition comprising the cell according to claim 6 .

8. A T cell expressing the CAR according to claim 4 .

9. A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject an anti-tumor effective amount of the cell according to claim 8 , wherein the cancer comprises leukemia, lymphoma, multiple myeloma, adenocarcinoma or carcinoma of the gastrointestinal tract, mammary gland, ovary, prostate, liver lung, kidney, or a combination thereof.

10. The T cell according to claim 8 , wherein said CAR is constitutively expressed.

11. A T cell comprising a chimeric antigen receptor comprising an extracellular domain comprising an scFv and the amino acid sequence encoded by SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2019
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 051443/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2018
From: ABKEN, HINRICH; HOMBACH, ANDREAS
To: MILTENYI BIOTEC GMBH
Reel/Frame 046302/0871 →